Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION After an FAERS cluster in a demographic the trials under-enrolled, phase-3 protocol with endpoint-sensitivity issues is what pediatric-plan strategist can touch in a 505(b)(2) program relying on literature plus a bridging study. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this Clinical and Evidence Strategy file.

DECISION Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. Pediatric-plan strategist can defend Proceed under protocol from phase-3 protocol with endpoint-sensitivity issues after an FAERS cluster in a demographic the trials under-enrolled in a Pharma & Life Sciences challenge. 2. Pediatric-plan strategist cannot defend Proceed under protocol from phase-3 protocol with endpoint-sensitivity issues; Pause the pathway is what the extract actually supports after an FAERS cluster in a demographic the trials under-enrolled. 3. An FAERS cluster in a demographic the trials under-enrolled never reached the population in phase-3 protocol with endpoint-sensitivity issues — reopen intake, do not close to drop a secondary. 4. Two facts in phase-3 protocol with endpoint-sensitivity issues after an FAERS cluster in a demographic the trials under-enrolled conflict for pediatric-plan strategist; hold this Clinical and Evidence Strategy file.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 2. Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after an FAERS cluster in a demographic the trials under-enrolled. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read phase-3 protocol with endpoint-sensitivity issues against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move to drop a secondary for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (phase-3 protocol with endpoint-sensitivity issues after an FAERS cluster in a demographic the trials under-enrolled). If phase-3 protocol with endpoint-sensitivity issues cannot force a Pharma & Life Sciences label under Clinical and Evidence Strategy, stop. Do not invent missing evidence a 505(b)(2) program relying on literature plus a bridging study does not have.